Research Progress in the Role of Tim3/galectin-9 in Hematological Malignancy--Review.
10.19746/j.cnki.issn.1009-2137.2021.04.056
- Author:
Dong-Qin YANG
1
;
Yu-Mei ZHANG
1
;
Ling-Yun WU
2
;
Dong WU
3
;
Chun-Kang CHANG
4
Author Information
1. Department of Hematology，The Eighth People's Hospital，Shanghai 200233，China.
2. Department of Hematology，The Eighth People's Hospital，Shanghai 200233，China,Department of Hematology，The Sixth People's Hospital，Shanghai Jiaotong University，Shanghai 200233，China.
3. Department of Hematology，The Sixth People's Hospital，Shanghai Jiaotong University，Shanghai 200233，China.
4. Department of Hematology，The Eighth People's Hospital，Shanghai 200233，China,Department of Hematology，The Sixth People's Hospital，Shanghai Jiaotong University，Shanghai 200233，China,E-mail: changchunkang7010@aliyun. com.
- Publication Type:Review
- MeSH:
CD8-Positive T-Lymphocytes;
Galectins;
Hematologic Neoplasms;
Hepatitis A Virus Cellular Receptor 2;
Humans;
Immunotherapy
- From:
Journal of Experimental Hematology
2021;29(4):1360-1364
- CountryChina
- Language:Chinese
-
Abstract:
The incidence of hematological malignant tumor is increasing year by year, and seriously affecting the human health. In addition to the traditional radiation and chemotherapy, immunotherapy has achieved a certain effect in the treatment of blood tumor, but it is limited by exhaustion of CD8
